«Lysomustine» is a new highly effective antitumor agent elaborated at the Institute of Organic Synthesis of the Ural Branch of the Russian Academy of Sciences (Ekaterinburg) in cooperation with the Blochin Russian Cancer Research Center of the Russian Academy of Medical Sciences (Moscow). Lysomustine has a chemical structure of alkylnitrosourea derivative. Original chemical structure of Lysomustine molecule provides its active transport through cytoplasmatic membranes of tumor cells. Lysomustine is less toxic and possesses a number of advantages as compared with known alkylnitrosoureas used in clinical practices. Lysomustine was permitted to clinical application for treatment of malignant melanoma and lung carcinoma. Pilot batches of Lysomustine substance are produced at OOO AKADEMFARM. (Ekaterinburg), and Lysomustine in the dosage form is produced at the OOO GLES (Moscow).

Lysomustine has an antimetastatic effect. There are clinically confirmed cases of the complete disappearance of the multiple metastases of lung cancer into the brain and liver. The low toxicity of the agent makes it possible to use Lysomustine for treatment of seriously ill and elderly patients.